Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.
2.

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.

Popat S, Matakidou A, Houlston RS.

J Clin Oncol. 2004 Feb 1;22(3):529-36. Review.

PMID:
14752076
3.

A systematic review of molecular and biological tumor markers in neuroblastoma.

Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):4-12. Review.

4.

Biostatistics and tumor marker studies in breast cancer: design, analysis and interpretation issues.

Biganzoli E, Boracchi P, Marubini E.

Int J Biol Markers. 2003 Jan-Mar;18(1):40-8. Review. No abstract available.

PMID:
12699062
5.

Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future.

Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA.

Br J Cancer. 2003 Apr 22;88(8):1191-8.

6.

The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG; Standards for Reporting of Diagnostic Accuracy..

Clin Chem. 2003 Jan;49(1):7-18.

7.

Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC; Standards for Reporting of Diagnostic Accuracy..

Clin Chem. 2003 Jan;49(1):1-6. Review.

8.

A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family.

Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, Lambert PC, Young B, Wailoo AJ, Lewis IJ.

Eur J Cancer. 2003 Jan;39(1):19-30. Review.

PMID:
12504654
9.

Prognostic factors in non-small cell lung cancer: a decade of progress.

Brundage MD, Davies D, Mackillop WJ.

Chest. 2002 Sep;122(3):1037-57. Review.

PMID:
12226051
10.
11.

Tumor markers as clinical cancer tests--are we there yet?

Schilsky RL, Taube SE.

Semin Oncol. 2002 Jun;29(3):211-2. No abstract available.

PMID:
12063673
12.

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA.

J Natl Cancer Inst. 2002 Jun 5;94(11):855-7.

PMID:
12048274
13.

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N.

J Natl Cancer Inst. 2002 Jun 5;94(11):852-4.

PMID:
12048273
14.
15.

Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies.

Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA.

Ann Epidemiol. 2002 Jan;12(1):1-6.

PMID:
11750233
16.

Systematic reviews of evaluations of prognostic variables.

Altman DG.

BMJ. 2001 Jul 28;323(7306):224-8. No abstract available.

17.

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials)..

JAMA. 2001 Apr 18;285(15):1987-91. Review.

PMID:
11308435
18.

The revised CONSORT statement for reporting randomized trials: explanation and elaboration.

Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, G√łtzsche PC, Lang T; CONSORT GROUP (Consolidated Standards of Reporting Trials)..

Ann Intern Med. 2001 Apr 17;134(8):663-94. Review.

PMID:
11304107
19.

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel..

J Clin Oncol. 2001 Mar 15;19(6):1865-78. Erratum in: J Clin Oncol 2001 Nov 1;19(21):4185-8. J Clin Oncol 2002 Apr 15;20(8):2213.

PMID:
11251019
20.

Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network.

McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, Grossman HB, Peng A, Taube SE, Waldman FM.

Clin Cancer Res. 2000 May;6(5):1854-64.

Items per page

Supplemental Content

Support Center